
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="../">
      
      
        <link rel="next" href="../Vector-systems/">
      
      
      <link rel="icon" href="../../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.6.23">
    
    
      
        <title>CAR Constructs - Multi-Modal Molecular Analyses for Living Drugs</title>
      
    
    
      <link rel="stylesheet" href="../../../assets/stylesheets/main.84d31ad4.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../../stylesheets/extra.css">
    
    <script>__md_scope=new URL("../../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    <body dir="ltr">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#car-constructs" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow md-header--lifted" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../../.." title="Multi-Modal Molecular Analyses for Living Drugs" class="md-header__button md-logo" aria-label="Multi-Modal Molecular Analyses for Living Drugs" data-md-component="logo">
      
  <img src="../../../images/Logo_light.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Multi-Modal Molecular Analyses for Living Drugs
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              CAR Constructs
            
          </span>
        </div>
      </div>
    </div>
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
  </nav>
  
    
      
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../Technologies/" class="md-tabs__link">
          
  
  
    
  
  Technologies

        </a>
      </li>
    
  

      
        
  
  
  
  
    
    
      <li class="md-tabs__item">
        <a href="../../Pipelines/" class="md-tabs__link">
          
  
  
    
  
  Pipelines

        </a>
      </li>
    
  

      
        
  
  
  
    
  
  
    
    
      <li class="md-tabs__item md-tabs__item--active">
        <a href="../" class="md-tabs__link">
          
  
  
    
  
  Resources

        </a>
      </li>
    
  

      
    </ul>
  </div>
</nav>
    
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


  

<nav class="md-nav md-nav--primary md-nav--lifted md-nav--integrated" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../../.." title="Multi-Modal Molecular Analyses for Living Drugs" class="md-nav__button md-logo" aria-label="Multi-Modal Molecular Analyses for Living Drugs" data-md-component="logo">
      
  <img src="../../../images/Logo_light.png" alt="logo">

    </a>
    Multi-Modal Molecular Analyses for Living Drugs
  </label>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    
    
      
        
          
        
      
    
    
    
      
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_1" >
        
          
          <div class="md-nav__link md-nav__container">
            <a href="../../Technologies/" class="md-nav__link ">
              
  
  
  <span class="md-ellipsis">
    Technologies
    
  </span>
  

            </a>
            
          </div>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_1_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_1">
            <span class="md-nav__icon md-icon"></span>
            Technologies
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
      
        
          
        
      
        
      
    
    
    
      
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_2" >
        
          
          <div class="md-nav__link md-nav__container">
            <a href="../../Pipelines/" class="md-nav__link ">
              
  
  
  <span class="md-ellipsis">
    Pipelines
    
  </span>
  

            </a>
            
              
              <label class="md-nav__link " for="__nav_2" id="__nav_2_label" tabindex="0">
                <span class="md-nav__icon md-icon"></span>
              </label>
            
          </div>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_2">
            <span class="md-nav__icon md-icon"></span>
            Pipelines
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
            
              
                
  
  
  
  
    
    
      
        
          
        
      
        
      
    
    
    
      
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_2_2" >
        
          
          <div class="md-nav__link md-nav__container">
            <a href="../../Pipelines/LivingDrugOmics-Pipeline/" class="md-nav__link ">
              
  
  
  <span class="md-ellipsis">
    LivingDrugOmics
    
  </span>
  

            </a>
            
              
              <label class="md-nav__link " for="__nav_2_2" id="__nav_2_2_label" tabindex="0">
                <span class="md-nav__icon md-icon"></span>
              </label>
            
          </div>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_2_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_2_2">
            <span class="md-nav__icon md-icon"></span>
            LivingDrugOmics
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
            
              
                
  
  
  
  
    
    
      
        
      
        
      
        
      
        
      
    
    
    
      
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_2_2_2" >
        
          
          <label class="md-nav__link" for="__nav_2_2_2" id="__nav_2_2_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    Documentation
    
  </span>
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="3" aria-labelledby="__nav_2_2_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_2_2_2">
            <span class="md-nav__icon md-icon"></span>
            Documentation
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../Pipelines/LivingDrugOmics-Pipeline/Documentation/params-file/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    Params File
    
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../Pipelines/LivingDrugOmics-Pipeline/Documentation/reference_building/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    Reference building
    
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../Pipelines/LivingDrugOmics-Pipeline/Documentation/cli/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    Command Line Arguments
    
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../Pipelines/LivingDrugOmics-Pipeline/Documentation/output/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    Output
    
  </span>
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
    
  
  
  
    
    
      
        
          
        
      
        
      
        
      
    
    
    
      
        
        
      
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--section md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3" checked>
        
          
          <div class="md-nav__link md-nav__container">
            <a href="../" class="md-nav__link ">
              
  
  
  <span class="md-ellipsis">
    Resources
    
  </span>
  

            </a>
            
              
              <label class="md-nav__link " for="__nav_3" id="__nav_3_label" tabindex="">
                <span class="md-nav__icon md-icon"></span>
              </label>
            
          </div>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            Resources
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
            
              
                
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
        
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          
  
  
  <span class="md-ellipsis">
    CAR Constructs
    
  </span>
  

          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  
  <span class="md-ellipsis">
    CAR Constructs
    
  </span>
  

      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#link-to-resources" class="md-nav__link">
    <span class="md-ellipsis">
      Link to Resources
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#fda-approved-car-t-cell-therapies" class="md-nav__link">
    <span class="md-ellipsis">
      FDA-Approved CAR T Cell Therapies
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#non-fda-approved-car-t-and-related-therapies" class="md-nav__link">
    <span class="md-ellipsis">
      Non-FDA Approved CAR T and Related Therapies
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../Vector-systems/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    Vector Systems
    
  </span>
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  



<h1 id="car-constructs">CAR Constructs<a class="headerlink" href="#car-constructs" title="Permanent link">&para;</a></h1>
<p>This page summarizes information on FDA-approved and non-approved chimeric antigen receptors (CAR) constructs. This serves as a comprehensive resource for researchers and bioinformaticians working with CAR T-cell profiling. </p>
<p>CAR constructs are categorized into different generations, each representing a stage of development. With each generation, specific enhancements are introducedâ€”such as the addition of co-stimulatory domains (e.g., CD28, 4-1BB), improvements in antigen-binding affinity, signaling strength, or persistence, and the incorporation of safety switches or logic gating. These modifications are designed to increase therapeutic efficacy, prolong cell survival, and reduce toxicity or off-target effects.</p>
<p>Below, both FDA-approved and non-approved CAR products are presented with detailed descriptions of their structural differences regarding the CAR construct. Precise knowledge of CAR sequences is essential for performing in-depth sequence analyses, including accurate identification of CAR expression, detection of potential mutations, assessment of binding affinities, and evaluation of immunogenicity, all critical for optimizing CAR design and functionality.</p>
<figure class="half-size">
  <img src="../../../images/resources/Abb_CAR_generations.png" alt="CAR generations">
  <figcaption>Image adapted from <a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1034707/full"> Tomasik et. al 2022 </a></figcaption>
</figure>

<h2 id="link-to-resources">Link to Resources<a class="headerlink" href="#link-to-resources" title="Permanent link">&para;</a></h2>
<div class="grid cards">
<ul>
<li>
<p><strong>CAR constructs</strong></p>
<hr />
<p>Get nuceleotide sequences <code>.fasta</code> and annotation information <code>.gtf</code></p>
<p><a href="https://github.com/fraunhofer-izi/Living-Drugs-Wiki/tree/main/Resources/CAR_constructs/Sequences"><img alt="ðŸ§¬" class="twemoji" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@15.1.0/assets/svg/1f9ec.svg" title=":dna:" /> Nucleotide sequence</a></p>
<p><a href="https://github.com/fraunhofer-izi/Living-Drugs-Wiki/tree/main/Resources/CAR_constructs/Annotations"><img alt="ðŸ“„" class="twemoji" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@15.1.0/assets/svg/1f4c4.svg" title=":page_facing_up:" /> Annotations</a></p>
</li>
</ul>
</div>
<h2 id="fda-approved-car-t-cell-therapies">FDA-Approved CAR T Cell Therapies<a class="headerlink" href="#fda-approved-car-t-cell-therapies" title="Permanent link">&para;</a></h2>
<figure>
  <img src="../../../images/resources/Abb_FDA_approved.png" alt="FDA-approved">
  <figcaption>Image adapted from <a href="doi:10.3390/biomedicines12081641">Grahnert et al. Biomedicines (2020)</a> *novel CD19 CAR (CAT = using a CAT131E10 hybridoma (CAT))</figcaption>
</figure>

<h3 id="fda-approved-car-t-cell-therapies-summary-table">FDA-Approved CAR T Cell Therapies â€“ Summary Table<a class="headerlink" href="#fda-approved-car-t-cell-therapies-summary-table" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Therapy Name</th>
<th>Approval Date</th>
<th>Antigen Target</th>
<th>Indication</th>
<th>Antigen Recognition</th>
<th>Spacer</th>
<th>Transmembrane</th>
<th>Signaling</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://www.drugs.com/pro/abecma.html">Idecabtagene Vicleucel (Abecma)</a></td>
<td>2021-03-26</td>
<td>BCMA</td>
<td>Multiple Myeloma</td>
<td>BCMA scFv (VHH1-G4S-VHH2)</td>
<td>CD8a hinge</td>
<td>CD8a transmembrane domain</td>
<td>4-1BB, CD3Î¶</td>
<td>https://www.drugs.com/pro/abecma.html</td>
</tr>
<tr>
<td><a href="https://www.drugs.com/pro/carvykti.html">Ciltacabtagene Autoleucel (Carvykti)</a></td>
<td>2022-02-28</td>
<td>BCMA</td>
<td>Multiple Myeloma</td>
<td>BCMA scFv (VHH1-G4S-VHH2)</td>
<td>CD8a hinge</td>
<td>CD8a transmembrane domain</td>
<td>4-1BB, CD3Î¶</td>
<td>https://www.drugs.com/pro/carvykti.html</td>
</tr>
<tr>
<td><a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel">Tisagenlecleucel (Kymriah)</a></td>
<td>2017-08-30</td>
<td>CD19</td>
<td>Acute Lymphocytic Leukemia</td>
<td>FMC63 (anti-CD19)</td>
<td>CD8 hinge</td>
<td>CD8 TMD</td>
<td>4-1BB, CD3Î¶</td>
<td>https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel</td>
</tr>
<tr>
<td><a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel">Axicabtagene Ciloleucel (Yescarta)</a></td>
<td>2017-10-18</td>
<td>CD19</td>
<td>B-cell Lymphoma</td>
<td>FMC63 (anti-CD19)</td>
<td>CD28 extracellular</td>
<td>CD28 TMD</td>
<td>CD28 intracellular, CD3Î¶</td>
<td>https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel</td>
</tr>
<tr>
<td><a href="https://www.drugs.com/pro/tecartus.html">Brexucabtagene Autoleucel (Tecartus)</a></td>
<td>2020-07-24</td>
<td>CD19</td>
<td>MCL / ALL</td>
<td>FMC63 (anti-CD19)</td>
<td>CD28 extracellular</td>
<td>CD28 TMD</td>
<td>CD28 intracellular, CD3Î¶</td>
<td>https://www.drugs.com/pro/tecartus.html, same design as Axi-Cel https://www.scienceboard.net/index.aspx?sec=ser&amp;sub=def&amp;pag=dis&amp;ItemID=3389</td>
</tr>
<tr>
<td><a href="https://www.drugs.com/pro/breyanzi.html">Lisocabtagene Maraleucel (Breyanzi)</a></td>
<td>2021-02-05</td>
<td>CD19</td>
<td>B-cell Lymphoma</td>
<td>FMC63 (anti-CD19)</td>
<td>IgG4 hinge</td>
<td>CD28 TMD</td>
<td>4-1BB, CD3Î¶</td>
<td>https://www.drugs.com/pro/breyanzi.html</td>
</tr>
<tr>
<td><a href="https://www.cgtlive.com/view/fda-approves-obe-cel-adults-relapsed-refractory-b-cell-precursor-acute-lymphoblastic-leukemia">Obecabtagene Autoleucel (Obe-cel / Aucatzyl)</a></td>
<td>2024-11-08</td>
<td>CD19</td>
<td>R/R B-cell precursor ALL</td>
<td>CAT131E10 (anti-CD19, low affinity)</td>
<td>CD8a hinge</td>
<td>CD8a TMD</td>
<td>4-1BB, CD3Î¶</td>
<td>https://www.cgtlive.com/view/fda-approves-obe-cel-adults-relapsed-refractory-b-cell-precursor-acute-lymphoblastic-leukemia</td>
</tr>
</tbody>
</table>
<h3 id="1-idecabtagene-vicleucel-abecma">1. <a href="https://www.drugs.com/pro/abecma.html"><strong>Idecabtagene Vicleucel (Abecma)</strong></a><a class="headerlink" href="#1-idecabtagene-vicleucel-abecma" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Indication:</strong> Multiple Myeloma</li>
<li><strong>Approval Date:</strong> March 26, 2021</li>
<li><strong>Antigen Target:</strong> BCMA (B-cell maturation antigen)</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li>CD8a signal peptide</li>
<li>BCMA scFv (VHH1 linker G4S VHH2)</li>
<li>CD8a hinge</li>
<li>CD8a transmembrane domain</li>
<li>CD137/4-1BB cytoplasmic</li>
<li>CD3Î¶ cytoplasmic</li>
</ul>
</li>
</ul>
<h3 id="2-ciltacabtagene-autoleucel-carvykti">2. <a href="https://www.drugs.com/pro/carvykti.html"><strong>Ciltacabtagene Autoleucel (Carvykti)</strong></a><a class="headerlink" href="#2-ciltacabtagene-autoleucel-carvykti" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Indication:</strong> Multiple Myeloma</li>
<li><strong>Approval Date:</strong> February 28, 2022</li>
<li><strong>Antigen Target:</strong> BCMA (B-cell maturation antigen)</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li>CD8a signal peptide</li>
<li>BCMA scFv (VHH1 linker G4S VHH2)</li>
<li>CD8a hinge</li>
<li>CD8a transmembrane domain</li>
<li>CD137/4-1BB cytoplasmic</li>
<li>CD3Î¶ cytoplasmic</li>
</ul>
</li>
</ul>
<h3 id="3-tisagenlecleucel-kymriah">3. <a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel"><strong>Tisagenlecleucel (Kymriah)</strong></a><a class="headerlink" href="#3-tisagenlecleucel-kymriah" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Indication:</strong> Acute Lymphocytic Leukemia</li>
<li><strong>Approval Date:</strong> August 30, 2017</li>
<li><strong>Antigen Target:</strong> CD19</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li>CD8 signal peptide</li>
<li>FMC63 (anti-CD19)</li>
<li>CD8alpha (hinge and TMD)</li>
<li>CD137/4-1BB</li>
<li>CD3Î¶</li>
</ul>
</li>
</ul>
<h3 id="4-axicabtagene-ciloleucel-yescarta">4. <a href="https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel"><strong>Axicabtagene Ciloleucel (Yescarta)</strong></a><a class="headerlink" href="#4-axicabtagene-ciloleucel-yescarta" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Indication:</strong> B-cell Lymphoma</li>
<li><strong>Approval Date:</strong> October 18, 2017</li>
<li><strong>Antigen Target:</strong> CD19</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li>CSF2RA signal peptide RefSeq</li>
<li>FMC63 (anti-CD19)</li>
<li>CD28 (part of extracellular, TMD, and intracellular)</li>
<li>CD3Î¶ (complete intracellular domain)</li>
</ul>
</li>
</ul>
<h3 id="5-brexucabtagene-autoleucel-tecartus">5. <a href="https://www.drugs.com/pro/tecartus.html"><strong>Brexucabtagene Autoleucel (Tecartus)</strong> </a><a class="headerlink" href="#5-brexucabtagene-autoleucel-tecartus" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Indication:</strong> Mantle Cell Lymphoma or Acute Lymphocytic Leukemia</li>
<li><strong>Approval Date:</strong> July 24, 2020 (MCL), October 1, 2021 (ALL)</li>
<li><strong>Antigen Target:</strong> CD19</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li>same design as Axicabtagene Ciloleucel (https://www.scienceboard.net/index.aspx?sec=ser&amp;sub=def&amp;pag=dis&amp;ItemID=3389) but different manufracturing process. </li>
</ul>
</li>
</ul>
<h3 id="6-lisocabtagene-maraleucel-breyanzi">6. <a href="https://www.drugs.com/pro/breyanzi.html"><strong>Lisocabtagene Maraleucel (Breyanzi)</strong></a><a class="headerlink" href="#6-lisocabtagene-maraleucel-breyanzi" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Indication:</strong> B-cell Lymphoma</li>
<li><strong>Approval Date:</strong> February 5, 2021</li>
<li><strong>Antigen Target:</strong> CD19</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li>anti-CD19 (FMC63)</li>
<li>IgG4 (hinge)</li>
<li>CD28 (TMD)</li>
<li>CD137/4-1BB</li>
<li>CD3Î¶</li>
</ul>
</li>
</ul>
<h3 id="7-obecabtagene-autoleucel-obe-cel-aucatzyl">7. <a href="https://www.cgtlive.com/view/fda-approves-obe-cel-adults-relapsed-refractory-b-cell-precursor-acute-lymphoblastic-leukemia"><strong>Obecabtagene Autoleucel (Obe-cel / Aucatzyl)</strong></a><a class="headerlink" href="#7-obecabtagene-autoleucel-obe-cel-aucatzyl" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Indication:</strong> Relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL)</li>
<li><strong>Approval Date:</strong> November 8, 2024 <a href="https://www.cgtlive.com/view/fda-approves-obe-cel-adults-relapsed-refractory-b-cell-precursor-acute-lymphoblastic-leukemia">Link</a></li>
<li><strong>Antigen Target:</strong> CD19</li>
<li><strong>CAR Construct Structure:</strong> <ul>
<li>anti-CD19 (novel CD19 CAR (CAT = using a CAT131E10 hybridoma (CAT)) with a lower affinity than FMC63)</li>
<li>CD8a (hinge and TMD)</li>
<li>CD137/4-1BB</li>
<li>CD3Î¶</li>
</ul>
</li>
</ul>
<h2 id="non-fda-approved-car-t-and-related-therapies">Non-FDA Approved CAR T and Related Therapies<a class="headerlink" href="#non-fda-approved-car-t-and-related-therapies" title="Permanent link">&para;</a></h2>
<h3 id="non-fda-approved-car-t-cell-therapies-summary-table">Non-FDA-Approved CAR T Cell Therapies - Summary Table<a class="headerlink" href="#non-fda-approved-car-t-cell-therapies-summary-table" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Therapy Name</th>
<th>CAR Design</th>
<th>Antigen Target</th>
<th>Indication</th>
<th>CAR Construct Structure</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://www.allogene.com/pipeline/allo-501">ALLO-501</a></td>
<td>Allogeneic</td>
<td>CD19</td>
<td>Non-Hodgkin Lymphoma</td>
<td>Allogeneic CAR; CD19-specific</td>
<td>https://www.allogene.com/pipeline/allo-501</td>
</tr>
<tr>
<td><a href="https://fatetherapeutics.com/pipeline/ft819/">FT819</a></td>
<td>Allogeneic</td>
<td>CD19</td>
<td>Relapsed/Refractory B-Cell Malignancies</td>
<td>Off-the-shelf iPSC-derived CD19 CAR T</td>
<td>https://fatetherapeutics.com/pipeline/ft819/</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03054298">Mesothelin CAR (Alnuctamab)</a></td>
<td>Bi-specific engager</td>
<td>BCMA and CD3</td>
<td>Relapsed/Refractory Multiple Myeloma</td>
<td>BiTE targeting BCMA on myeloma and CD3 on T cells</td>
<td>https://clinicaltrials.gov/study/NCT03054298</td>
</tr>
<tr>
<td><a href="https://www.kyvernatx.com/pipeline/kyv-101">KYV-101</a></td>
<td>Conventional CD19 CAR</td>
<td>CD19</td>
<td>Autoimmune diseases (e.g., lupus nephritis)</td>
<td>Hu19 scFv, CD8a hinge/TMD, CD28, CD3Î¶</td>
<td>https://www.kyvernatx.com/pipeline/kyv-101</td>
</tr>
<tr>
<td><a href="https://www.atarabio.com/pipeline/ata2271/">ATA2271</a></td>
<td>Conventional single target</td>
<td>Mesothelin</td>
<td>Solid Tumors</td>
<td>Mesothelin-targeted CAR T</td>
<td>https://www.atarabio.com/pipeline/ata2271/</td>
</tr>
<tr>
<td><a href="https://ashpublications.org/blood/article/142/Supplement%201/219/499690/BMS-986393-CC-95266-a-G-Protein-Coupled-Receptor">GPRC5D CAR</a></td>
<td>Conventional single target</td>
<td>GPRC5D</td>
<td>Relapsed/Refractory Multiple Myeloma</td>
<td>GPRC5D-targeted CAR in early clinical development</td>
<td>https://ashpublications.org/blood/article/142/Supplement%201/219/499690/BMS-986393-CC-95266-a-G-Protein-Coupled-Receptor</td>
</tr>
<tr>
<td><a href="https://jitc.bmj.com/content/11/6/e006699">APRIL-based CAR</a></td>
<td>Dual-targeting</td>
<td>BCMA and TACI</td>
<td>Multiple Myeloma</td>
<td>APRIL protein domain 116â€“250; IgG1/CD8 spacers</td>
<td>https://jitc.bmj.com/content/11/6/e006699</td>
</tr>
<tr>
<td><a href="https://www.gracellbio.com/pipeline/gc012f">GC012F</a></td>
<td>Dual-targeting</td>
<td>BCMA and CD19</td>
<td>Multiple Myeloma</td>
<td>Dual-target CAR T, phase 1/2</td>
<td>https://www.gracellbio.com/pipeline/gc012f</td>
</tr>
<tr>
<td><a href="https://poseida.com/pipeline/p-bcma-101/">P-BCMA-101</a></td>
<td>Safety switch</td>
<td>BCMA</td>
<td>Multiple Myeloma</td>
<td>BCMA CAR with safety switch, memory T cells</td>
<td>https://poseida.com/pipeline/p-bcma-101/</td>
</tr>
<tr>
<td><a href="https://aacrjournals.org/clincancerres/article/31/3/503/751210/Phase-I-Study-of-ROR1-Specific-CAR-T-Cells-in">ROR1 CAR</a></td>
<td>Safety switch</td>
<td>ROR1</td>
<td>Leukemia, lymphoma, solid tumors</td>
<td>R11/R12 scFv, CD28, 4-1BB, CD3Î¶, EGFR safety switch</td>
<td>https://aacrjournals.org/clincancerres/article/31/3/503/751210/Phase-I-Study-of-ROR1-Specific-CAR-T-Cells-in</td>
</tr>
</tbody>
</table>
<h3 id="1-april-based-car-t-cell-therapy-jitc-2023">1. <a href="https://jitc.bmj.com/content/11/6/e006699"><strong>APRIL-based CAR T Cell Therapy</strong> â€“ JITC (2023)</a><a class="headerlink" href="#1-april-based-car-t-cell-therapy-jitc-2023" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Status:</strong> Not yet FDA approved (Wang et al., 2021)</li>
<li><strong>Antigen Target:</strong> Dual-antigen CAR: BCMA and TACI (Cyclophilin Ligand Interactor)</li>
<li><strong>Indication:</strong> Multiple Myeloma</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li><strong>Patent:</strong> No17 (Patent April)</li>
<li><strong>Protein Region:</strong> 116-250 of APRIL protein (Uniprot 075888)</li>
<li><strong>Signal Peptide:</strong> IgK k chain V-III</li>
<li><strong>Scaffold:</strong> CAR scaffold comprising IgG1 hinge spacer, CD8 alpha spacer, or IgG1 Fc domain</li>
</ul>
</li>
</ul>
<h3 id="2-ror1-car-t-cell-therapy-clinical-cancer-research-2024">2. <a href="https://aacrjournals.org/clincancerres/article/31/3/503/751210/Phase-I-Study-of-ROR1-Specific-CAR-T-Cells-in"><strong>ROR1 CAR T Cell Therapy</strong> â€“ Clinical Cancer Research (2024)</a><a class="headerlink" href="#2-ror1-car-t-cell-therapy-clinical-cancer-research-2024" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Status:</strong> Study by Osorio-Rodriguez (2023)</li>
<li><strong>Antigen Target:</strong> ROR1</li>
<li><strong>Indication:</strong> Leukemia, lymphoma, and some solid tumors overexpress ROR1</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li><strong>ScFv:</strong> R11 or R12-scFv (mouse cells do not carry R12)</li>
<li><strong>Hinge:</strong> IG4-hinge</li>
<li><strong>Costimulatory Domains:</strong> CD28, 4-1BB</li>
<li><strong>Signaling Domain:</strong> CD3Î¶</li>
<li><strong>Additional Components:</strong> T2A viral protein (ribosomal skipping), truncated EGFR (safety switch to detect CAR+ expressing cells with anti-EGFR antibody)</li>
</ul>
</li>
</ul>
<h3 id="3-mesothelin-directed-car-t-therapy-nct03054298-clinicaltrialsgov">3. <a href="https://clinicaltrials.gov/study/NCT03054298"><strong>Mesothelin-Directed CAR T Therapy (NCT03054298)</strong> â€“ ClinicalTrials.gov</a><a class="headerlink" href="#3-mesothelin-directed-car-t-therapy-nct03054298-clinicaltrialsgov" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Status:</strong> <a href="https://clinicaltrials.gov/study/NCT03054298">NCT03054298</a></li>
<li><strong>Antigen Target:</strong> Simultaneously binds myeloma cells expressing BCMA and T cells (via CD3)</li>
<li><strong>Indication:</strong> Relapsed/Refractory Multiple Myeloma (RRMM)</li>
<li><strong>Drug:</strong> Alnuctamab (Bi-specific T Cell Engager)</li>
<li><strong>References:</strong><ul>
<li><a href="https://ashpublications.org/blood/article/140/Supplement%201/400/491672/Alnuctamab-ALNUC-BMS-986349-CC-93269-a-B-Cell">ASH Publications</a></li>
<li><a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(17)30016-8#secsectitle0080">Cell Cancer</a></li>
</ul>
</li>
</ul>
<h3 id="4-gprc5d-car-t-bms-986393-cc-95266-ash-publications">4. <a href="https://ashpublications.org/blood/article/142/Supplement%201/219/499690/BMS-986393-CC-95266-a-G-Protein-Coupled-Receptor"><strong>GPRC5D CAR T (BMS-986393 / CC-95266)</strong> â€“ ASH Publications</a><a class="headerlink" href="#4-gprc5d-car-t-bms-986393-cc-95266-ash-publications" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Status:</strong> Early-stage clinical trials</li>
<li><strong>Antigen Target:</strong> GPRC5D</li>
<li><strong>Indication:</strong> Multiple Myeloma (Relapsed/Refractory)</li>
<li><strong>Clinical Trial:</strong> <a href="https://ashpublications.org/blood/article/142/Supplement%201/219/499690/BMS-986393-CC-95266-a-G-Protein-Coupled-Receptor">BMS-986393/CC-95266</a></li>
<li><strong>References:</strong><ul>
<li><a href="https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V20.1.202314/494129/GPRC5D-The-Next-Frontier-for-Immunotherapy-in">ASH Publications</a></li>
</ul>
</li>
</ul>
<h3 id="5-kyv-101-kyverna-therapeutics-company-website">5. <a href="https://www.kyvernatx.com/pipeline/kyv-101"><strong>KYV-101 (Kyverna Therapeutics)</strong> â€“ Company Website</a><a class="headerlink" href="#5-kyv-101-kyverna-therapeutics-company-website" title="Permanent link">&para;</a></h3>
<ul>
<li><strong>Status:</strong> Early clinical trials</li>
<li><strong>Antigen Target:</strong> CD19</li>
<li><strong>Indication:</strong> KYV-101 was developed by Kyverna Therapeutics for the treatment of B cell-driven autoimmune diseases, such as lupus nephritis, systemic sclerosis, myasthenia gravis, and stiff-person syndrome</li>
<li><strong>CAR Construct Structure:</strong><ul>
<li>Construct C19 binding domain (Hu19)</li>
<li>CD8a hinge and transmembrane domain</li>
<li>CD28 co-stimulatory domain</li>
<li>CD3Î¶ activation domain</li>
</ul>
</li>
</ul>
<h4 id="6-gc012f-gracell-biotechnologies-gracell-pipeline">6. <a href="https://www.gracellbio.com/pipeline/gc012f"><strong>GC012F (Gracell Biotechnologies)</strong> â€“ Gracell Pipeline</a><a class="headerlink" href="#6-gc012f-gracell-biotechnologies-gracell-pipeline" title="Permanent link">&para;</a></h4>
<ul>
<li><strong>Status:</strong> Phase 1/2</li>
<li><strong>Indication:</strong> Multiple Myeloma</li>
<li><strong>Mechanism:</strong> A dual-target CAR T cell therapy currently in the transition between phases 1 and 2, as safety data support further trials.</li>
</ul>
<h4 id="7-p-bcma-101-poseida-therapeutics-company-website">7. <a href="https://poseida.com/pipeline/p-bcma-101/"><strong>P-BCMA-101 (Poseida Therapeutics)</strong> â€“ Company Website</a><a class="headerlink" href="#7-p-bcma-101-poseida-therapeutics-company-website" title="Permanent link">&para;</a></h4>
<ul>
<li><strong>Status:</strong> Phase 2</li>
<li><strong>Antigen Target:</strong> BCMA</li>
<li><strong>Indication:</strong> Multiple Myeloma</li>
<li><strong>Mechanism:</strong> P-BCMA-101 is a novel chimeric antigen receptor (CAR)-T cell therapeutic targeting BCMA, which is highly expressed on multiple myeloma cells. It is designed to increase efficacy while minimizing toxicity through reduced immunogenicity, lack of tonic signaling, a safety switch, and a product composed predominantly of early memory T cells that are effectively all CAR-positive.</li>
</ul>
<h4 id="8-ata2271-atara-biotherapeutics-company-pipeline">8. <a href="https://www.atarabio.com/pipeline/ata2271/"><strong>ATA2271 (Atara Biotherapeutics)</strong> â€“ Company Pipeline</a><a class="headerlink" href="#8-ata2271-atara-biotherapeutics-company-pipeline" title="Permanent link">&para;</a></h4>
<ul>
<li><strong>Status:</strong> Phase 1</li>
<li><strong>Antigen Target:</strong> Mesothelin</li>
<li><strong>Indication:</strong> Solid Tumors</li>
<li><strong>Mechanism:</strong> ATA2271 is a mesothelin-targeting CAR T cell therapy for solid tumors, currently in phase 1 trials to establish safety and initial efficacy.</li>
</ul>
<h3 id="allogenic-car-t-cells">Allogenic CAR T cells<a class="headerlink" href="#allogenic-car-t-cells" title="Permanent link">&para;</a></h3>
<h4 id="1-allo-501-allogene-therapeutics-company-pipeline">1. <a href="https://www.allogene.com/pipeline/allo-501"><strong>ALLO-501 (Allogene Therapeutics)</strong> â€“ Company Pipeline</a><a class="headerlink" href="#1-allo-501-allogene-therapeutics-company-pipeline" title="Permanent link">&para;</a></h4>
<ul>
<li><strong>Status:</strong> Phase 2</li>
<li><strong>Indication:</strong> Non-Hodgkin Lymphoma</li>
<li><strong>Mechanism:</strong> An allogeneic CAR T cell therapy aiming to provide a safer and more accessible off-the-shelf option.</li>
</ul>
<h4 id="2-ft819-fate-therapeutics-company-pipeline">2.  <a href="https://fatetherapeutics.com/pipeline/ft819/"><strong>FT819 (Fate Therapeutics)</strong> â€“ Company Pipeline</a><a class="headerlink" href="#2-ft819-fate-therapeutics-company-pipeline" title="Permanent link">&para;</a></h4>
<ul>
<li><strong>Status:</strong> Phase 1</li>
<li><strong>Indication:</strong> Relapsed/Refractory B-Cell Malignancies</li>
<li><strong>Antigen Target:</strong> CD19</li>
<li><strong>Mechanism:</strong> Off-the-shelf iPSC-derived CAR T therapy. </li>
</ul>












                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/fraunhofer-izi" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      <script id="__config" type="application/json">{"base": "../../..", "features": ["navigation.tabs", "navigation.tabs.sticky", "navigation.indexes", "toc.integrate"], "search": "../../../assets/javascripts/workers/search.973d3a69.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../../assets/javascripts/bundle.f55a23d4.min.js"></script>
      
    
  </body>
</html>